North America accounts for the largest share of H1N1 vaccine sales worldwide, as stated by the new market research report on H1N1 Vaccines. Rapid growth in birth cohorts in developing countries, coupled with the improvement in access to public and private healthcare and increased spending, entail a growing demand for vaccines in the developing world. Notably, the 2009 H1N1 pandemic resulted in widespread panic in China and India, partly due to the respective government’s unpreparedness to handle the disease outbreak. The governments in these countries are expected to continue domestic production and stockpiling of reserve H1N1 vaccine doses in the near term. Increasing public awareness about influenza vaccines, coupled with the need to safeguard the population in the event of a future outbreak, will continue to drive sales of H1N1 vaccines.
Key players covered in the report include Baxter International Inc., CPL Biologicals Pvt. Ltd., CSL Limited, bioCSL, GlaxoSmithKline Plc., MedImmune LLC, Novartis AG, Sanofi Pasteur SA, Sinovac Biotech Ltd., and Zydus Cadilla.
The research report titled “H1N1 Vaccines: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides an in-depth study of the key factors influencing the performance of H1N1 influenza va
Copyright©2012 Vocus, Inc.
All rights reserved